Home Biosimilar Antibodies Immunology & Inflammation IL Receptor Benralizumab (Anti-IL-5Ra/ CD125)
For research use only. Not for use in humans.

Benralizumab (Anti-IL-5Ra/ CD125)

Synonyms: IL5R alpha， CD125

Benralizumab (Anti-IL-5Ra/ CD125) is an afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra) with potential anti-asthmatic activity. MW: 145.5 kD.

Benralizumab (Anti-IL-5Ra/ CD125)

Quality Control

Batch: A242701 Purity: 99% Protein concentration: 8.96mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Benralizumab (Anti-IL-5Ra/ CD125) is an afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra) with potential anti-asthmatic activity. MW: 145.5 kD.

Product Details

CAS No. 1044511-01-4
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06501807 RECRUITING Drug: Biologic treatments available in Chronic Rhinosinusiti Rhinosinusitis Chronic; Nasal Polyps University Hospital, Lille 2024-07-11
NCT05692180 ACTIVE_NOT_RECRUITING Drug: Benralizumab|Drug: Placebo Asthma AstraZeneca 2023-04-05 PHASE3
NCT07444567 RECRUITING Drug: Benralizumab Asthma; Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilic Syndrome (HES) AstraZeneca 2026-07-24 PHASE3
NCT06734884 NOT_YET_RECRUITING Drug: Benralizumab 30 MG/ML [Fasenra]|Drug: Placebo Comparat DRESS Syndrome University Hospital, Lille 2027-01-06 PHASE2
NCT06750289 RECRUITING Eosinophilic Asthma AstraZeneca 2025-03-28 PHASE3
NCT06512883 RECRUITING Drug: Benralizumab Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilia Syndrome (HES) AstraZeneca 2025-04-17 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-05-18)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.